Patents
Sitemap › C12 - Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation or genetic engineering › C12N - Micro-organisms or enzymes; Compositions thereof; Propagating, preserving, or maintaining micro-organisms; Mutation or genetic engineering; Culture media › C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Patents for C12N 7 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof (26,637)
12/2000
12/12/2000US6159712 Methods for enhancing the production of interferon in cell culture
12/12/2000US6159478 Genetic engineering
12/09/2000CA2307933A1 Replicating or semi-replicating viral constructs, preparation and uses for gene delivery
12/07/2000WO2000073507A2 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
12/07/2000WO2000073482A1 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
12/07/2000WO2000073481A1 Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
12/07/2000WO2000073480A1 Compositions and methods for production of recombinant virus using a carrier vector derived from a nonmammalian virus
12/07/2000WO2000073478A2 Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
12/07/2000WO2000073476A1 Vector for integration of heterologous sequences into poxviral genomes
12/07/2000WO2000073445A2 Interleukin-1-receptor associated kinase-3 (irak3)
12/07/2000WO2000073424A1 A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
12/07/2000WO2000073423A1 Packaging cell
12/07/2000WO2000073335A1 Cytotoxic t-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy
12/07/2000WO2000073319A1 Method for enhanced protein stabilization and production of cell lines useful for production of such stabilized proteins
12/07/2000WO2000073316A2 Virus immunologic determinants
12/07/2000WO2000048703B1 Purification of biological substances
12/07/2000WO2000042561A3 Oligonucleotide mediated nucleic acid recombination
12/07/2000WO2000039304A9 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
12/07/2000DE19925199A1 Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie Cytotoxic T cell epitopes of the papillomavirus L1 protein and its use in diagnosis and therapy
12/07/2000CA2376116A1 Promotion or inhibition of angiogenesis and cardiovascularization
12/07/2000CA2375802A1 Cytotoxic t-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy
12/07/2000CA2375147A1 Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
12/07/2000CA2375123A1 Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
12/07/2000CA2375119A1 Compositions and methods for production of recombinant virus using a carrier vector derived from a nonmammalian virus
12/07/2000CA2374597A1 Methods and compositions for lowering the level of tumor necrosis factor (tnf) in the tnf-associated disorders
12/07/2000CA2372243A1 Method for enhanced protein stabilization and production of cell lines useful for production of such stabilized proteins
12/07/2000CA2372242A1 Virus immunologic determinants
12/06/2000EP1057889A1 Enhanced immunogen for inactivated vaccine for infection with japanese encephalitis viruses and process for producing the same
12/06/2000EP1056880A1 Methods for purified aav vector production
12/06/2000EP1056878A1 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
12/06/2000EP1056838A1 Method for the development of an hiv vaccine
12/06/2000EP1056837A1 Method and apparatus for irradiating a biological fluid
12/05/2000US6156887 Compositions and methods for the treatment and diagnosis of immune disorders
12/05/2000US6156558 Alphavirus RNA replicon systems
12/05/2000US6156542 Preparing raw cytokines; purifying leukocytes, culture leukocytes, adjust heat, incubate with cytokine, incubate with sendai virus, lower heat, incubate with sendai virus and separate leukocytes from cytokines
12/05/2000US6156498 Establishment of HHV-8+ lymphoma cell line, virus produced, antibody, diagnostic method and kit for detecting HHV-8 infection
12/05/2000US6156497 Hybrid plasmids for the expression of heterologous proteins and irreversible genetic adjustment to tissues
12/05/2000US6156314 Monoclonal antibodies
12/05/2000US6156303 Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
11/2000
11/30/2000WO2000071737A2 Improved retroviral production by inhibition of the enveloppe cell receptor
11/30/2000WO2000071731A1 Phage-dependent super-production of biologically active protein and peptides
11/30/2000WO2000071726A1 Methods to inhibit infectious agent transmission during xenotransplantation
11/30/2000WO2000071700A1 Methods for separating, fractionating and analyzing gene of virus existing in water
11/30/2000WO2000071678A1 Inducible packaging cell lines for lentivirus vectors
11/30/2000WO2000071561A1 Cd4-independent hiv envelope proteins as vaccines and therapeutics
11/30/2000WO2000071078A2 Composition designed for implementing an antitumoral or antiviral treatment in a mammal
11/30/2000WO2000046355A3 Telomerase reverse transcriptase transcriptional regulatory sequences
11/30/2000WO2000022136A3 Recombinant e1a deleted adenoviral vectors
11/30/2000CA2375032A1 Cd4-independent hiv envelope proteins as vaccines and therapeutics
11/30/2000CA2374941A1 Composition designed for implementing an antitumoral or antiviral treatment in a mammal
11/30/2000CA2374517A1 Inducible packaging cell lines for lentivirus vectors
11/29/2000EP1054991A1 Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors
11/29/2000EP1054989A1 Methods for pseudoadenoviral vector production
11/29/2000EP1054988A1 Anti-viral vectors
11/29/2000EP1054955A2 Compositions comprising viruses and methods for concentrating virus preparations
11/29/2000CN1058993C Prepn. and use of molecular chimera for treatment of cancer
11/28/2000US6153435 Nucleotide sequences coding hybrid envelope polypetides; for gene therapy
11/28/2000US6153380 In vitro mehtod by introducing library of random nucleic acids into cells to produce peptides, screening for cells exhibiting an altered phenotype; better intracellular localization of peptides
11/28/2000US6153378 Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus
11/28/2000US6153201 Oral immunization with papillomavirus virus-like particles
11/28/2000US6153199 Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
11/23/2000WO2000070070A1 Paramyxoviridae virus vector defective in envelope gene
11/23/2000WO2000070024A2 Infectious retroviruses from a leukemic dog cell line with extensive homologies to murine leukemia viruses
11/23/2000WO2000069269A1 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
11/23/2000WO2000042560A3 Methods for making character strings, polynucleotides and polypeptides
11/23/2000WO2000032221A3 Promotion or inhibition of angiogenesis and cardiovascularization
11/23/2000WO2000029556A3 Identification of glycosphingolipids that promote hiv-1 entry into cells
11/23/2000WO2000012740A3 Adenoviruses deleted in the iva2, 100k and/or preterminal protein sequences
11/23/2000WO1999065871A3 Thiolesters and uses thereof
11/23/2000DE19923027A1 Verfahren zur Inaktivierung von Viren A method of inactivating viruses
11/23/2000DE19918446A1 Verwendung von Coxsackievirus B3 zur Verbesserung der Transfektion von Zellen Use of coxsackievirus B3 to improve the transfection of cells
11/23/2000CA2373486A1 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
11/23/2000CA2368948A1 Envelope gene-deficient virus vector of paramyxoviridae
11/22/2000EP1053754A1 Method of inactivating viruses
11/22/2000EP1053341A1 Use of negative regulation elements for nerve-specific expression of transgenes
11/22/2000EP1053013A1 Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
11/21/2000US6150131 Screening for viricides that suppress interactions between cysteine and palmitic acid; mix cells infected with influenza virus, palmitic acid and modulator, monitor reduction in palmitic acid incorporation
11/21/2000US6150109 Lipophilic quenching of viral inactivating agents
11/21/2000US6150093 Unique associated Kaposi's sarcoma virus sequences and uses thereof
11/21/2000US6150087 Non-hepatitis a or b virus polypeptide which is capable of illiciting immune response with hepatitus virus antibodies, for the treatment of and prevention of viral infections
11/21/2000US6149918 The cell line contains a human herpesvirus type 8 virus particle and does not contain epstein barr virus; for the production of antibodies or screening a biological sample of the human suspected of being infected with virus
11/21/2000US6149917 Culturing, inoculating the cells with japanese encephalitis virus, propagating and multiplying the virus, harvesting, purifying viruses by ion-exchange chromatographic process, adsorption chromatography and gel permeation
11/16/2000WO2000068394A1 Epoxide hydrolases of aspergillus origin
11/16/2000WO2000068390A2 Plant recombination proteins
11/16/2000WO2000068386A1 Autotaxin variants and uses to treat diseases of metabolism
11/16/2000WO2000068379A1 Methods for treating tumors using antiangiogenic compounds
11/16/2000WO2000067786A1 PRODUCTION OF NOVEL NEWCASTLE DISEASE VIRUS STRAINS FROM cDNAS AND IMPROVED LIVE ATTENUATED NEWCASTLE DISEASE VACCINES
11/16/2000WO2000067784A1 Bacteriophage isolated from bacterial genomes and extrachromosomal elements and methods of use thereof
11/16/2000WO2000029561A3 Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
11/16/2000WO2000006717A9 Improved transformation efficiency in phage display through modification of a coat protein
11/16/2000CA2372805A1 Autotaxin variants and uses to treat diseases of metabolism
11/16/2000CA2372699A1 Methods for treating tumors using antiangiogenic compounds
11/15/2000EP1051620A1 Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein ib alpha
11/15/2000CN1273603A Attenuated respiratory syncytial viruses
11/14/2000US6146891 Methods for cultivating cells and propagating viruses
11/14/2000US6146874 Method of preparing recombinant adeno-associated virus compositions
11/14/2000US6146873 Growing continuous culture of monkey kidney cells for more than one generation in protein-free media, infecting with virus, selecting for desired phenotype, and isolating virus; for influenza vaccine
11/14/2000US6146643 A hepatitis a virus having a genome consisting of a human attenuated hepatitis a virus sequence wherein the 5' noncoding region has been replaced by the 5' noncoding region of simian hepatitis a virus agm-27
11/14/2000US6146642 Recombinant new castle disease virus RNA expression systems and vaccines
11/14/2000CA1341140C Structural phosphoprotein (pp28) of human cytomegalovirus (hcmv), the preparation and use thereof
1 ... 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 ... 267